id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-1167-0017,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability; Correction,Notice,Correction,2017-11-17T05:00:00Z,2017,11,2017-11-17T05:00:00Z,,2017-11-17T20:10:11Z,2017-24948,0,0,0900006482c8a43d
FDA-2014-D-1167-0016,FDA,FDA-2014-D-1167,Draft Guidance for Industry on Controlled Correspondence Related to Generic Drug Development,Other,Guidance,2017-11-03T04:00:00Z,2017,11,2017-11-03T04:00:00Z,,2022-12-22T13:58:49Z,,0,0,0900006482c3ee67
FDA-2014-D-1167-0015,FDA,FDA-2014-D-1167,"Controlled Correspondence Related to Generic Drug Development; 
Draft Guidance for Industry; Availability",Notice,Notice of Availability,2017-11-03T04:00:00Z,2017,11,2017-11-03T04:00:00Z,2018-01-03T04:59:59Z,2018-01-03T02:01:35Z,2017-23947,0,0,0900006482c3e633